Different effect of antiulcer agents on rat cysteamine-induced duodenal ulcer after sialoadenectomy, but not gastrectomy.
Bedekovic. Vlado V; Mise. Stjepan S; Anic. Tomislav T; Staresinic. Mario M; Gjurasin. Miroslav M; Kopljar. Mario M; Kalogjera. Livije L; Drvis. Petar P; Boban Blagaic. Alenka A; Batelja. Lovorka L; Seiwerth. Sven S; Sikiric. Predrag P
Key Findings
- BPC‑157 prevented cysteamine‑induced duodenal ulcers in normal rats and in rats without salivary glands.
- Standard anti‑ulcer drugs (ranitidine, omeprazole, atropine) lost their protective effect after salivary gland removal.
- The protective action of BPC‑157 appears independent of gastric acid suppression and may replace missing salivary factors.
Practical Outcomes
- For biohackers interested in gut health, BPC‑157 shows promise as a gut‑protective agent that works even when typical ulcer meds fail, suggesting a unique mechanism. However, the data are from a rat model with high doses given by injection, so human dosing and safety are still unknown. Use this as a cue to watch for clinical trials on BPC‑157 for ulcer or inflammatory bowel conditions, rather than self‑administering at this stage.
Summary
In rats, the peptide BPC‑157 stopped duodenal ulcers caused by a chemical, even when the animals had their salivary glands removed. Common ulcer drugs (like ranitidine, omeprazole, and atropine) only worked when the salivary glands were intact, showing they need something from saliva to be effective. This suggests BPC‑157 works through a different, saliva‑independent protective pathway.
Abstract
The focus was on salivary glands in cysteamine-induced duodenal ulcer and the different effects of antiulcer agents on cysteamine-induced duodenal ulcer in sialoadenectomized but not gastrectomized rats. We tested antiulcer agents on cysteamine-induced duodenal ulcer in rats (agents/kg i.p.) simultaneously with cysteamine 400 mg/kg s.c., rat killed 24 h thereafter subjected to no surgery (normal), to gastrectomy (24 h before) or sialoadenectomy, acute (24 h before) or chronic (21 days before). (i) Ulcerogenesis: cysteamine-induced duodenal ulcer had the same severity and incidence in normal, gastrectomized or acutely or chronically sialoadenectomized rats. (ii) Antiulcer effect under normal conditions or following gastrectomy: in normal or gastrectomized rats all agents tested, gastric pentadecapeptide BPC 157 [currently in clinical trials for inflammatory bowel disease (PL-10, PLD-116, PL-14736, Pliva) (10.0 microg or 10.0 ng), ranitidine (10 mg), atropine (10 mg), omeprazole (10 mg)] inhibited cysteamine-induced duodenal ulcers, acting through gastric acid-independent mechanisms. Following sialoadenectomy, acute or chronic: ranitidine, omeprazole and atropine were completely ineffective, while pentadecapeptide BPC 157 could protect. Thus, we found that contrary to stomach, salivary glands are implicated in cytoprotective agent activity (standard agents were ineffective after sialoadenectomy). Also, gastric pentadecapeptide BPC 157 was consistently associated with a cytoprotective effect, suggesting a beneficial activity distinctive from that of H2-receptor blockers, proton-pump inhibitors and anticholinergics; but probably replacing missing salivary glands factors.
Study Information
pubmed
2003
2003-09-05T00:00:00.000Z
10.1016/j.ejphar.2003.08.013